行情

BMRN

BMRN

拜玛林制药
NASDAQ

实时行情|Nasdaq Last Sale

79.60
-0.23
-0.29%
盘后: 79.60 0 0.00% 17:13 04/08 EDT
开盘
79.98
昨收
79.83
最高
81.74
最低
78.88
成交量
150.09万
成交额
--
52周最高
97.10
52周最低
62.88
市值
143.22亿
市盈率(TTM)
-544.4596
分时
5日
1月
3月
1年
5年

分析师评级

25位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BMRN价格均价为117.64,最高价位164.00,最低价为77.00。

EPS

BMRN 新闻

更多
  • Is BioMarin Pharmaceuticals Stock a Buy?
  • MotleyFool.com · 17小时前
  • Vertex Pharmaceuticals And BioMarin Pharmaceutical: 2 Safe Biotech Picks To Buy During This Bear Market
  • Seeking Alpha - Article · 1天前
  • Biomarin to File Regulatory Applications for Vosoritide in Q3
  • Zacks · 1天前
  • BioMarin readies vosoritide applications in U.S. and Europe
  • seekingalpha · 2天前

所属板块

制药
+2.77%
制药与医学研究
+2.82%

热门股票

代码
价格
涨跌幅

BMRN 简况

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
展开

微牛提供BioMarin Pharmaceutical Inc.(NASDAQ-BMRN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BMRN股票新闻,以帮助您做出投资决策。